Buy Prograf Online

What is Prograf?

Prograf (tacrolimus) lowers your body's immune system. The immune system helps your body fight infections. The immune system can also fight or "reject" a transplanted organ such as a liver or kidney. This is because the immune system treats the new organ as an invader.

Prograf is used together with other medicines to prevent your body from rejecting a heart, liver, or kidney transplant.

Prograf may also be used for purposes not listed in this medication guide.

Important information about Prograf

Prograf may increase your risk of developing serious infections, cancer, or transplant failure. Talk with your doctor about the risks and benefits of using this medication.

You will need regular medical tests to be sure Prograf is not causing harmful effects. Do not miss any follow up visits to your doctor for blood or urine tests. Avoid being near people who are sick or have infections.

Prograf can harm your kidneys, and this effect is increased when you also use certain other medicines harmful to the kidneys. Before using Prograf, tell your doctor about all other medicines you use. Many other drugs (including some over-the-counter medicines) can be harmful to the kidneys.

Call your doctor right away if you have symptoms of a serious brain infection, such as a change in your mental state, problems with speech or walking, or decreased vision. These symptoms may start gradually and get worse quickly.

Before taking Prograf

You should not use Prograf if you are allergic to tacrolimus or hydrogenated castor oil, or if you have used cyclosporine (Neoral, Sandimmune, Gengraf) within the past 24 hours.

Prograf can lower blood cells that help your body fight infections, or cause your body to produce too much of a certain type of white blood cells. This can lead to serious and sometimes fatal conditions, including cancer, a severe brain infection that can lead to disability or death, or a virus that can cause failure of a transplanted kidney.

Using Prograf may increase your risk of developing skin cancer, especially if you are treated over long periods of time with drugs that weaken the immune system. Talk with your doctor about your specific risk.

Some people taking Prograf after a kidney transplant have developed diabetes. This effect has been seen most often in people who are Hispanic or African-American. Talk with your doctor about your individual risk of diabetes if you have concerns.

To make sure you can safely take Prograf, tell your doctor if you have any of these other conditions:

  • kidney or liver disease;

  • heart disease, high blood pressure, high cholesterol or triglycerides (a type of fat in the blood);

  • if you also use sirolimus (Rapamune); or

  • if you are using other drugs that weaken your immune system such as cancer medicine or steroids.

FDA pregnancy category C. It is not known whether Prograf will harm an unborn baby. Tell your doctor if you are pregnant or plan to become pregnant while using this medication.

Tacrolimus can pass into breast milk and may harm a nursing baby. You should not breast-feed while you are using Prograf.

How should I take Prograf?

Take Prograf exactly as prescribed by your doctor. Do not take in larger or smaller amounts or for longer than recommended. Follow the directions on your prescription label. Your doctor may occasionally change your dose to make sure you get the best results.

You may receive an injection of Prograf shortly after your transplant. Prograf injection is given until you are ready to take the pill form of Prograf.

The Prograf capsule is usually taken every 12 hours. Take the medicine at the same time each day. You may take Prograf with or without food, but take it the same way each time.

You will need regular medical tests to be sure this medication is not causing harmful effects. Visit your doctor regularly. Do not miss any follow up visits to your doctor for blood or urine tests.

Store at room temperature away from moisture and heat.

What happens if I miss a dose?

Take the missed dose as soon as you remember. Skip the missed dose if it is almost time for your next scheduled dose. Do not take extra medicine to make up the missed dose.

What happens if I overdose?

Seek emergency medical attention or call the Poison Help line at 1-800-222-1222.

What should I avoid while taking Prograf?

Grapefruit and grapefruit juice may interact with Prograf and lead to potentially dangerous effects. Do not use grapefruit products while you are taking Prograf.

Avoid being near people who are sick or have infections. Tell your doctor at once if you develop signs of infection.

Avoid exposure to sunlight or tanning beds. Prograf can make you sunburn more easily. Wear protective clothing and use sunscreen (SPF 30 or higher) when you are outdoors.

Do not receive a "live" vaccine while using Prograf. The vaccine may not work as well during this time, and may not fully protect you from disease. Live vaccines include measles, mumps, rubella (MMR), Bacillus Calmette-Guérin (BCG), oral polio, rotavirus, smallpox, typhoid, yellow fever, varicella (chickenpox), zoster (shingles), and nasal flu (influenza) vaccine.

Prograf side effects

Get emergency medical help if you have any of these signs of an allergic reaction to Prograf: hives; difficult breathing; swelling of your face, lips, tongue, or throat.

Call your doctor at once if you have a serious side effect such as:

  • fever, chills, body aches, flu symptoms, sores in your mouth and throat;

  • change in your mental state, problems with speech or walking, decreased vision (may start gradually and get worse quickly);

  • pale or yellowed skin, dark colored urine, confusion or weakness;

  • feeling light-headed or short of breath, rapid heart rate, trouble concentrating;

  • pain in the lower back or side, blood in your urine, pain or burning when you urinate;

  • urinating less than usual or not at all;

  • dry cough, cough with mucus or blood, sweating, wheezing, gasping for breath, chest pain;

  • tremors (shaking), seizure (convulsions);

  • high potassium (slow heart rate, weak pulse, muscle weakness, tingly feeling);

  • low magnesium (jerky muscle movements, muscle weakness or limp feeling, slow reflexes);

  • high blood pressure (severe headache, blurred vision, buzzing in your ears, anxiety, chest pain, shortness of breath, uneven heartbeats); or

  • high blood sugar (increased thirst, increased urination, hunger, dry mouth, fruity breath odor, drowsiness, dry skin, blurred vision, weight loss).

Less serious Prograf side effects may include:

  • nausea, stomach pain, diarrhea, constipation;

  • headache;

  • sleep problems (insomnia); or

  • swelling in your hands or feet.

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

What other drugs will affect Prograf?

Prograf can harm your kidneys. This effect is increased when you also use other medicines harmful to the kidneys, such as: chemotherapy, antiviral medication, pain or arthritis medicine, injected antibiotics, or medicines to treat a bowel disorder or prevent organ transplant rejection. You may need dose adjustments or special tests if you have recently used any of these medications.

Many drugs can interact with Prograf. Below is just a partial list. Tell your doctor about all other medicines you use, especially:

  • other medicines to prevent rejection of a transplanted organ;

  • St. John's wort;

  • antacids such as Amphojel, Maalox, Mylanta, Rolaids, Rulox, and others;

  • an antibiotic such as azithromycin (Zithromax, Zmax, Z-Pack), clarithromycin (Biaxin), erythromycin (E.E.S., EryPed, Ery-Tab, Erythrocin, Pediazole), levofloxacin (Levaquin), rifabutin (Mycobutin), rifampin (Rifadin, Rifater, Rifamate), and others;

  • an antidepressant such as desipramine (Norpramin) or nefazodone;

  • antifungal medication such as caspofungin (Cancidas), clotrimazole (Mycelex Troche), itraconazole (Sporanox), ketoconazole (Nizoral), posaconazole (Noxafil), or voriconazole (Vfend);

  • a barbiturate such as phenobarbital (Solfoton);

  • birth control pills or hormone replacement;

  • heart or blood pressure medication such as amiodarone (Cordarone, Pacerone), amlodipine (Norvasc, Caduet, Exforge, Lotrel, Tekamlo, Tribenzor, Twynsta, Amturnide), diltiazem (Cardizem, Cartia, Dilacor, Diltia, Diltzac, Taztia, Tiazac), dronedarone (Multaq), nifedipine (Nifedical, Procardia), quinidine (Quin-G), verapamil (Calan, Covera, Isoptin, Verelan, Tarka), and others;

  • HIV/AIDS medication such as atazanavir (Reyataz), efavirenz (Sustiva, Atripla), fosamprenavir (Lexiva), nelfinavir (Viracept), ritonavir (Norvir, Kaletra), and others;

  • the hepatitis C medications boceprevir (Victrelis) or telaprevir (Incivek);

  • seizure medication such as carbamazepine (Carbatrol, Equetro, Tegretol), phenytoin (Dilantin), and others;

  • steroid medicine such as dexamethasone (Cortastat, Dexasone, Solurex, DexPak) or methylprednisolone (Medrol); or

  • stomach acid reducers such as cimetidine (Tagamet), lansoprazole (Prevacid), or omeprazole (Prilosec, Zegerid).

This list is not complete and there are many other drugs that can interact with Prograf. Tell your doctor about all medications you use. This includes prescription, over-the-counter, vitamin, and herbal products. Do not start a new medication without telling your doctor. Keep a list of all your medicines and show it to any healthcare provider who treats you.

For the Consumer

Applies to tacrolimus: oral capsule, oral capsule extended release

Along with its needed effects, tacrolimus (the active ingredient contained in Prograf) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor immediately if any of the following side effects occur while taking tacrolimus:

More common
  • Abdominal pain
  • abnormal dreams
  • agitation
  • anxiety
  • chills
  • confusion
  • convulsions (seizures)
  • diarrhea
  • dizziness
  • fever and sore throat
  • flu-like symptoms
  • frequent urination
  • headache
  • infection
  • itching
  • loss of appetite
  • loss of energy or weakness
  • mental depression
  • muscle trembling or twitching
  • nausea
  • nervousness
  • pale skin
  • seeing or hearing things that are not there
  • shortness of breath
  • skin rash
  • swelling of the feet or lower legs
  • tingling
  • trembling and shaking of the hands
  • trouble with sleeping
  • unusual bleeding or bruising
  • unusual tiredness or weakness
  • vomiting
Less common
  • Blurred vision
  • chest pain
  • increased sensitivity to pain
  • muscle cramps
  • numbness or pain in the legs
  • ringing in the ears
  • sweating
  • Enlarged heart
  • flushing of the face or neck
  • general feeling of discomfort or illness
  • weight loss
  • wheezing
Incidence not known
  • Black, tarry stools
  • blistering, peeling, loosening of the skin
  • bloating
  • bloody urine
  • blurred vision
  • constipation
  • cough
  • drowsiness
  • fainting
  • fast, slow, or irregular heartbeat
  • heartburn
  • increased blood pressure
  • increased thirst
  • indigestion
  • joint or muscle pain
  • lightheadedness
  • loss of appetite
  • lower back or side pain
  • nausea
  • pinpoint red spots on skin
  • pounding or rapid pulse
  • red, irritated eyes
  • red skin lesions, often with a purple center
  • shortness of breath
  • skin sores
  • stomach pain
  • troubled breathing
  • ulcers or white spots in mouth or on lips
  • weakness
  • weight gain
  • yellow eyes or skin

Some side effects of tacrolimus may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

More common
  • Acid or sour stomach
  • belching
  • difficulty with moving
  • lack or loss of strength
  • muscle pain or stiffness
  • unable to sleep
Less common
  • Body aches or pain
  • burning or stinging of the skin
  • cracks in the skin
  • crying
  • delusions
  • dementia
  • depersonalization
  • dysphoria
  • euphoria
  • excessive muscle tone
  • feeling of constant movement of self or surroundings
  • feeling that others are watching you or controlling your behavior
  • feeling that others can hear your thoughts
  • increased sensitivity of the skin to sunlight
  • large, flat, blue or purplish patches in the skin
  • loss of strength or energy
  • muscle tension or tightness
  • painful blisters on the trunk of the body
  • painful cold sores or blisters on the lips, nose, eyes, or genitals
  • paranoia
  • quick to react or overreact emotionally
  • rapidly changing moods
  • redness or other discoloration of the skin
  • restlessness
  • scaly skin
  • sensation of spinning
  • severe mood or mental changes
  • severe sunburn
  • sleepiness or unusual drowsiness
  • sore mouth or tongue
  • sores on the skin
  • swelling or inflammation of the mouth
  • tender, swollen glands in the neck
  • unusual behavior
  • white patches in the mouth, tongue, or throat
Incidence not known
  • Change in color vision
  • decreased weight
  • difficulty seeing at night
  • feeling hot and cold
  • hearing loss
  • sudden sweating

Tags: cheap prograf, buy cheap prograf, buy prograf, purchase tacrolimus online, purchase prograf online, order prograf, prograf, generic tacrolimus, purchase prograf, buy cheap tacrolimus, buy tacrolimus, order tacrolimus, order tacrolimus online, purchase tacrolimus, buy prograf online, buy tacrolimus online

Applies to tacrolimus: intravenous solution, oral capsule, oral capsule extended release


Respiratory side effects have included pleural effusion (30% to 32%), atelectasis (5% to 28%), dyspnea (3% to 29%), interstitial lung disease, voice changes, asthma, bronchitis, increased cough, emphysema, hiccups, lung disorder, pneumothorax, pulmonary edema, pharyngitis, pneumonia, respiratory disorder, rhinitis, sinusitis, and voice alteration. Bronchial anastomotic dehiscence has also been reported, including fatal cases in lung transplant patients treated with a combination of tacrolimus (the active ingredient contained in Prograf) sirolimus, and corticosteroids. In addition, a case of bronchiolitis obliterans organizing pneumonia has been reported, although the role of tacrolimus in this case is not clear.


Nephrotoxicity has been reported in approximately 52% of kidney transplantation patients and in 40% and 36% of liver transplantation patients receiving tacrolimus (the active ingredient contained in Prograf) in the U.S. and European randomized trials, respectively, and in 59% of heart transplantation patients in a European randomized trial. Use of tacrolimus with sirolimus in heart transplantation patients in a US study was associated with increased risk of renal function impairment, and is not recommended. More overt nephrotoxicity is seen early after transplantation, characterized by increasing serum creatinine and a decrease in urine output.

In 61 patients receiving tacrolimus for orthotopic liver transplantation, early postoperative renal insufficiency (as defined by creatinine 1.5-3.0 mg/dl occurring between post-op day 0 and 30) was observed in 43% of patients. Early acute renal failure (as defined by creatinine greater than 3.0 mg/dL) was observed in 18% of patients treated with tacrolimus. Approximately 8% of patients with acute renal failure required hemodialysis. New onset of late renal failure (as defined by creatinine greater than 3.0 mg/dl occurring between post-op day 30 to 365) was observed in 7% of patients receiving tacrolimus. The late onset renal failure seemed to occur as a result of severe infection with concomitant multi-organ failure syndrome. These data suggest that the etiology of early and late renal failure associated with tacrolimus therapy may be different.

The mechanism of tacrolimus-induced renal dysfunction is not well established. Animal data indicate that tacrolimus may cause efferent arteriolar vasoconstriction which leads to a reduction in glomerular filtration rate. Renal toxicity appears to be dose-related, although toxicity may still occur even at suggested therapeutic concentrations.

The use of a 24 hour continuous intravenous infusion as opposed to a short intravenous infusion may reduce the incidence and severity of renal toxicity.

Renal side effects have included elevations in serum creatinine (up to 39%) and blood urea nitrogen (up to 30%), and renal failure (up to 20%), sometimes requiring hemodialysis. In addition, oliguria and hematuria have been reported.

Nervous system

Nervous system side effects including headache (22% to 64%), tremors (24% to 56%), and paresthesias or dysesthesias (21% to 40%) have been reported. More serious nervous system effects have included posterior reversible encephalopathy syndrome (PRES), progressive multifocal leukoencephalopathy (PML),
mental status changes, seizures, encephalopathy, coma, dysarthria, aphasia, akinetic mutism, and neuropathy. In addition, dizziness, fatigue, incoordination, and hypertonia have also been reported. Abnormal dreams, agitation, amnesia, anxiety, confusion, convulsion, crying, depression, dizziness, elevated mood, emotional lability, encephalopathy, hemorrhagic stroke, hallucinations, hypertonia, incoordination, monoparesis, myoclonus, nerve compression, nervousness, neuropathy, flaccid paralysis, impaired psychomotor skills, psychosis, quadriparesis, somnolence, abnormal thinking , and impaired writing have been reported less frequently.

In 61 patients receiving tacrolimus for orthotopic liver transplantation, moderate to severe CNS toxicity in the early post-op course occurred in 21% of patients. Late toxicity occurred in 13% of patients. Most patients recovered following drug withdrawal or dose reduction. However, late neurotoxicity was highly associated with severe infections and multi-organ failure. Intravenous or high levels of tacrolimus may contribute to drug-associated neurotoxicity, but this remains to be confirmed.

Leukoencephalopathy has been reported in 3 patients receiving liver or lung transplants. Headaches, nausea, vomiting and fever accompanied by generalized seizures were thought to be due to an immunosuppression related demyelinating syndrome caused by tacrolimus toxicity. Another report details a patient who was switched from tacrolimus to cyclosporine therapy but developed the same syndrome. Neurological signs and symptoms should resolve within 1 to 2 weeks after discontinuation or dose reduction of tacrolimus. The mechanism by which tacrolimus (and cyclosporine) result in CNS demyelination is unknown, but may involve binding to intracellular protein ligands and inhibition of calcineurin activity.


Psychiatric side effects including insomnia (28% to 64%), nightmares (5% to 7%), depression, irritability, agitation, anxiety, hallucinations, abnormal dreams, and psychosis have been reported.


Infectious complications result in significant morbidity and mortality in immunosuppressed patients. Some studies have found a lower incidence of infection in tacrolimus-treated patients compared to cyclosporine-treated patients, however, comparisons were usually with historical controls. Other studies have failed to find any difference in the incidence of infectious complications.

Cytomegalovirus is the most frequently encountered viral pathogen in patients treated with tacrolimus (the active ingredient contained in Prograf) Patients who receive CMV-positive grafts are at increased risk of invasive CMV infection.

Bacterial infections, primarily gram-positive and gram-negative aerobes, and fungal infections are also encountered.

Immunologic side effects have included infectious complications as a result of immunosuppression.


In one patient who developed severe anemia, a bone marrow biopsy revealed selective hypoplasia of erythropoiesis. Erythropoietin levels were normal. The anemia resolved following infusions of erythrocyte concentrates and discontinuation of tacrolimus (the active ingredient contained in Prograf) The authors of this case report suggested a direct toxic effect of tacrolimus on the bone marrow.

Immune-mediated mechanisms have been suggested in other forms of tacrolimus-induced blood dyscrasias, such as hemolytic anemias and thrombocytopenia.

Hematologic side effects including anemia, leukocytosis, thrombocytopenia, ecchymoses, thrombotic thrombocytopenia purpura, coagulation disorder, ecchymosis, hematocrit increased, hemoglobin abnormal, hypochromic anemia, leukocytosis, leukopenia, polycythemia, prothrombin decreased, serum iron decreased, hemolytic anemia, and hemolytic uremic syndrome have been reported. Postmarketing adverse event reports have included agranulocytosis, disseminated intravascular coagulation, hemolytic anemia, neutropenia, pancytopenia, pure red cell aplasia, thrombocytopenic purpura, and thrombotic thrombocytopenic purpura.


Hyperkalemia may be severe. In some patients, potassium-restricted diets, potassium binding resins, and/or mineralocorticoids may be required to control the hyperkalemia. Potassium-sparing diuretics should be avoided.

The mechanism by which tacrolimus (the active ingredient contained in Prograf) produces hyperglycemia is not known. However, tacrolimus is concentrated in the pancreas and it may inhibit pancreatic insulin secretion.

Insulin therapy is only temporarily required in some patients, while long-term use is necessary in others. In one study of 52 liver transplants in 46 patients, 7 patients (13.6%) who were not diabetic prior to transplantation required insulin therapy after transplantation. Three of these patients required insulin for three months. Two remained normoglycemic after discontinuing insulin while the other was controlled on an oral hypoglycemic.

In another study of 81 liver transplant recipients, 17% of tacrolimus-treated patients required insulin therapy at 3 months posttransplant and 17.5% of cyclosporine-treated patients required insulin therapy at 3 months posttransplant.

Posttransplant diabetes mellitus has been reported in a greater percentage of tacrolimus-treated versus cyclosporine-treated kidney transplant patients (20% versus 4%, respectively). Insulin dependence was reversible in 15% of tacrolimus patients at one year and in 50% at two years. A similar warning should be noted for liver transplant patients.

Hypomagnesemia in renal transplant recipients results from renal magnesium wasting.

Metabolic side effects have included hyperglycemia (29% to 47%), sometimes requiring insulin therapy, hyperkalemia (10% to 46%), hypokalemia (11% to 29%), hypomagnesemia (15% to 48%), hyperlipidemia, acidosis, alkalosis, hyperphosphatemia, hypocalcemia, hypophosphatemia, hyponatremia, and hypoproteinemia.


In one study of 936 transplant patients receiving tacrolimus (the active ingredient contained in Prograf) as primary immunosuppressive therapy, posttransplant lymphoproliferative disease (PTLD) occurred in 15 (1.6%) patients. Serologic evidence of Epstein-Barr virus infections was found in all 15 patients. The median time between transplant and diagnosis of PTLD was 4.4 months. Disseminated PTLD was associated with a poor prognosis.

Oncologic side effects, or the development of new malignancies, are of particular concern in posttransplant patients. Lymphoproliferative disorders are most commonly encountered. Lymphadenopathy and monoclonal and polyclonal B cell hyperplasia as well as malignant, often fatal, B cell lymphomas have been reported.


Cardiovascular side effects have included hypertension (31% to 62%) and peripheral edema (10% to 26%) as well as chest pain, pericardial effusion, hypotension, ECG abnormalities, tachycardia, Torsades de pointes, QT prolongation, myocardial hypertrophy, and hypertrophic cardiomyopathy. Angina pectoris, cardiac fibrillation, cardiopulmonary failure, chest pain, deep thrombophlebitis, abnormal ECG, echocardiogram abnormal, electrocardiogram QRS complex abnormal, electrocardiogram ST segment abnormal, heart rate decreased, hemorrhage, hypotension, postural hypotension, peripheral vascular disorder, phlebitis, tachycardia, thrombosis, and vasodilatation have been reported less frequently. One case of bradycardia has been reported.

Tacrolimus-induced hypertension, while typically mild to moderate, may be severe in some patients. Treatment with antihypertensive agents may be necessary. However, potassium-sparing diuretics should be avoided due to the potential for tacrolimus to cause hyperkalemia.


Gastrointestinal side effects have included diarrhea, nausea, vomiting, and constipation. Anorexia, cholangitis, duodenitis, dyspepsia, dysphagia, esophagitis, flatulence, gastritis, gastroesophagitis, gastrointestinal hemorrhage, GGT increase, jaundice, GI perforation, ileus, increased appetite, ulcerative esophagitis, oral moniliasis, pancreatic pseudocyst, rectal disorder, and stomatitis have been reported less frequently.


Hepatic side effects have included elevations in liver function tests in up to 36% of patients. More serious hepatotoxicity, including jaundice, cholestatic jaundice, granulomatous hepatitis, hepatitis, have been uncommon.


Dermatologic effects such as pruritus (11% to 36%), rash (8% to 24%), alopecia, hirsutism, photosensitivity, and sweating have been reported. A case of eyelash trichomegaly has also been reported.


Acute rhabdomyolysis occurred on day 128 in an 18 month old female receiving tacrolimus (the active ingredient contained in Prograf) for bone marrow transplantation prophylaxis and control of graft-versus-host-disease. Tacrolimus blood trough levels were elevated at 30 to 60 ng/mL (normal 10-20 ng/mL) for a 3 week period. The patient died on day 130 due to acute renal failure due to severe acute rhabdomyolysis.

Musculoskeletal side effects have been uncommon. Rhabdomyolysis, arthralgia, myalgia, generalized spasm, leg cramps, myasthenia, and osteoporosis have been reported.


Other side effects of tacrolimus (the active ingredient contained in Prograf) therapy have included pain, fever, asthenia, enlarged abdomen, abscess, accidental injury, cellulitis, chills, fall, feeling abnormal, flu syndrome, generalized edema, hernia, decreased mobility, peritonitis, sepsis, temperature intolerance, ulcer, ear pain, otitis media, and tinnitus.


Ocular side effects including abnormal vision and amblyopia have been reported infrequently.


Genitourinary side effects including albuminuria, bladder spasm, cystitis, dysuria, hematuria, hydronephrosis, kidney failure, kidney tubular necrosis, nocturia, oliguria, pyuria, toxic nephropathy, urge incontinence, urinary frequency, urinary incontinence, urinary retention, BK nephropathy, and vaginitis have been reported infrequently.


Hypersensitivity side effects including allergic reaction have been reported infrequently.